TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01433016
Drug: 13C Sodium Octanoate
Normalized name: Octanoic acid
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.
Study: NCT03239899
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive one dose of 2mg/kg of pembrolizumab IV at Week 0.
Study: NCT01064817
Drug: PRM-151
Normalized name: Serum amyloid P protein (recombinant human PRM 151)
DrugBank: Zinpentraxin alfa (DB14852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
Study: NCT01438086
Drug: mecasermin
Normalized name: mecasermin
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracoronary bolus
Study: NCT01438086
Drug: 0.9% sodium chloride injection
Normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary bolus
Study: NCT02015546
Drug: Vilazodone
Normalized name: Vilazodone
DrugBank: Vilazodone (DB06684)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will receive Vilazodone at 10, 20 or 40mg.
Study: NCT00597038
Drug: Dasatinib and Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm A/ Phase I Potential Dose Levels.~Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m\^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m\^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m\^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m\^2.~Arm B/Phase II Potential Dose Levels.~MTD1: Dasatinib 70 mg; DTIC 1000 mg/m\^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m\^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m\^2.
Study: NCT00257283
Drug: Omega-3-acid ethyl esters 90
Normalized name: Omega-3-acid ethyl esters 90
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00396422
Drug: RWJ-445380
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01130467
Drug: methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.
Study: NCT01130467
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).
Study: NCT00557921
Drug: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin
Normalized name: Butalbital and Aspirin Tablets
DrugBank: Butalbital (DB00241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
Study: NCT00557921
Drug: Plavix (clopidogrel 75 mg) and aspirin
Normalized name: clopidogrel 75 MG [Plavix]
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: (CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
Study: NCT00003663
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04581265
Drug: albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received a single dose of albumin-bound paclitaxel (nab-PTX) 270mg/m2/d, administered intravenously (IV) on Day 1; Ifosfamide 1.2g/m2/d administered intravenously (IV) on Day 2-6; Cisplatin 20mg/m2/d administered intravenously (IV) on Day 2-6.
Study: NCT01794000
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT00965081
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks
Study: NCT01203735
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800mg per day for entire period of RT
Study: NCT02558517
Drug: prednisone discontinuation
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: randomization
Study: NCT03700801
Drug: Premixed insulin therapy group
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection therapy with insulin aspart 30 in patients with T2DM
Study: NCT00117637
Drug: Sorafenib (Nexavar, BAY43-9006)
Normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multi kinase inhibitor
Study: NCT00738699
Drug: MORAb-003 (farletuzumab)
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
Study: NCT00738699
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00117637
Drug: Interferon
Normalized name: Interferon
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon
Study: NCT01744249
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
Study: NCT01744249
Drug: Sandostatin LAR
Normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
Study: NCT01712126
Drug: Irbesartan and Hydrochlorothiazide
Normalized name: Irbesartan and Hydrochlorothiazide Tablets
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01712126
Drug: Avalide
Normalized name: Avalide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02417883
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evaluate urinary excretion rate fo furosemide
Study: NCT01476007
Drug: oral Cobalamin (vitamin B12)
Normalized name: mecobalamin / vitamin B12
DrugBank: Cobalamin (DB14098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention group: oral Optovite® B12 1000 gammas.
Study: NCT01476007
Drug: intramuscular Cobalamin (vitamin B12)
Normalized name: mecobalamin / vitamin B12
DrugBank: Cobalamin (DB14098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control group: intramuscular Optovite® B12 1000 gammas.
Study: NCT01135134
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The study drug is MFNS (50 μg spray device) and the dose will be:~* 5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks
Study: NCT01546558
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1000 mg bid on Days 1-10
Study: NCT01546558
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine 500 mg bid on Days 6-10
Study: NCT00134303
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is used.
Study: NCT05283551
Drug: Famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Famciclovir (500mg BD)
Study: NCT00675246
Drug: Betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)
Study: NCT04033367
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT00255190
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 12 months.
Study: NCT00255190
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 12 months.
Study: NCT03439501
Drug: avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Study drug: Avelumab (PD-L1 inhibitor; MSB0010718C)~* Dosage: 10 mg per body weight (kg) of a subject every two weeks~* One cycle consists of two injection of avelumab (28 days).~* The treatment cycle will be repeated until progression of disease or unacceptable toxicity and dose adjustments are permitted for patients who are unable to tolerate the side effects of drugs within each cycle.
Study: NCT00889135
Drug: droxidopa
Normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droxidopa (L-DOPS) comes in capsule form, 100 mg or 200 mg strength and is usually administered 2 - 3 times per day. It would be taken indefinitely to improve symptoms of orthostatic hypotension
Study: NCT03679065
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
Study: NCT03679065
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
Study: NCT00085358
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intraperitoneally
Study: NCT00085358
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or intraperitoneally
Study: NCT00085358
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02296424
Drug: ACZ885 150 mg (Canakinumab)
Normalized name: canakinumab 150 MG/ML
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
Study: NCT00000152
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000152
Drug: Beta-Carotene
Normalized name: Beta-carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02452918
Drug: Oritavancin
Normalized name: Oritavancin
DrugBank: Oritavancin (DB04911)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT02452918
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as a concomitant medication at a standard dose and dosing schedule
Study: NCT01495663
Drug: I-131-CLR1404
Normalized name: I-131-CLR1404
DrugBank: Iopofosine I-131 (DB15244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Description:~* Dosimetry: IV, 5 mCi, single dose, 6-day duration~* Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year
Study: NCT02368665
Drug: Amlodipine 5mg
Normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - Daily oral administration for 8 weeks
Study: NCT02368665
Drug: Amlodipine 5mg, Candesartan cilexetil 16mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - Daily oral administration Amlodipine 5mg for 8 weeks
Study: NCT02368665
Drug: Amlodipine 10mg, Candesartan cilexetil 16mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - After 8 weeks of administration, Amlodipine 10mg and Candesartan cilexetil 16mg once a day for 8 weeks
Study: NCT04371575
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There is no actual intervention as the study is observational. First choice tratment is Carbamzepine and Oxcarbazepine. In medically refractory patients, first choice surgery is microvascular decompression
Study: NCT01244113
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: optimization of propofol dose from 1.5 mg/kg to 2.5 mg/kg using Dixon's up and down method during MRI scanning
Study: NCT00989937
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 IU BID or 40 IU BID
Study: NCT01965119
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg via 2 hour IV infusion, single dose
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg via 2 hour IV infusion, 6 doses over 22 days
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg via SC injection, single dose
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg via SC injection, 6 doses over 22 days
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg via 2 hour IV infusion, single dose
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg via 2 hour IV infusion, single dose
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg via SC injection, single dose
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg via SC injection, single-dose
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg via 2 hour IV infusion, 6 doses over 22 days
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg via 2 hour IV infusion, 6 doses over 22 days
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg via SC injection, 6 doses over 22 days
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg via SC injection, 6 doses over 22 days
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
Study: NCT00734240
Drug: ISIS 353512
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
Study: NCT01536717
Drug: Articaine hydrochloride 2% solution
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * 4 ml/h periosteal wound infusion~* duration of 72 h
Study: NCT01536717
Drug: Sodium Chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo Sodium chloride 0,9%
Study: NCT03131206
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Oral, BID~* Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~* Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days.
Study: NCT00657943
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin tablets 2 g x 2
Study: NCT04537793
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granules for oral administration.
Study: NCT00657943
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: insulin as requested
Study: NCT02271464
Drug: Maintenance:BEVACIZUMAB
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~- BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks)
Study: NCT02271464
Drug: Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~* BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),~* CAPECITABINE 500 mg/tid orally, continuously,~* CYCLOPHOSPHAMIDE 50 mg/day orally, continuously.
Study: NCT00971802
Drug: PF-03882845 or Placebo
Normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03882845 20 mg or Placebo, daily for 10 days.
Study: NCT00657943
Drug: insulin aspart + insulin aspart protamin
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: insulin as requested
Study: NCT00657943
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: insulin as requested
Study: NCT00783133
Drug: Desloratadine 5 mg
Normalized name: desloratadine 5 MG
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarinex 5 mg daily x 7 days
Study: NCT00783133
Drug: fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allegra 180 mg daily x 7 days
Study: NCT00971802
Drug: PF-03882845 or Placebo
Normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03882845 60 mg or Placebo, daily for 10 days.
Study: NCT00971802
Drug: PF-03882845 or Placebo
Normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03882845 120 mg or Placebo, daily for 10 days.
Study: NCT00971802
Drug: PF-03882845 or Placebo
Normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03882845 185 mg or Placebo, daily for 10 days.
Study: NCT02218684
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02218684
Drug: Lacidipine
Normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01994642
Drug: Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01885949
Drug: Tivozanib
Normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral
Study: NCT02767271
Drug: Luliconazole Cream 1%
DrugBank: Luliconazole (DB08933)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Luliconazole cream will be applied topically per schedule specified in the arms.
Study: NCT01885949
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT01059890
Drug: cefotaxime
Normalized name: Cefotaxime
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00027625
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00027625
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes